Expanded access treatment for autoimmune PAP
Part of Lungs & breathing clinical trials.
This program provides an experimental inhaled medication to people with a rare lung condition called autoimmune pulmonary alveolar proteinosis (aPAP), where the immune system attacks the lungs. The treatment, molgramostim, is given through a nebulizer and may help improve breathing and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of autoimmune PAP (aPAP) and a positive blood test for the specific antibody.
- You must have at least one symptom of aPAP, such as shortness of breath, cough, or fatigue.
- You agree to use effective contraception during the study.
- You must not have used GM-CSF treatment in the last month or other investigational drugs recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an inhaled medicine called molgramostim for children with autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition. The goal is to see if the drug can improve lung function and reduce the need for whole lung lavage (a washing procedure).
This study tests ways to help Spanish-speaking Hispanic adults use their PAP (positive airway pressure) machine more regularly to treat sleep apnea. If you qualify, you'll get extra support to stick with your treatment.
This trial tests a new way to deliver a protein called GM-CSF directly into the lungs through a tube during a bronchoscopy. It may help people with autoimmune pulmonary alveolar proteinosis (aPAP) breathe better and improve lung function.
This early-phase study tests a treatment that uses gene-corrected immune cells to treat hPAP, a rare lung condition. The goal is to check safety and see whether the treatment improves breathing and lung function.
This study keeps a national record of people with pulmonary alveolar proteinosis (PAP). It includes one “snapshot” group and one group that follows people with autoimmune PAP and asks about symptoms and quality of life.
This Phase 1/2 study tests whether breathing in albuterol can improve symptoms or lung function in people with lymphangioleiomyomatosis (LAM). It’s mainly about safety and early signs of benefit by targeting airflow problems.
Hear when a new Autoimmune Pulmonary Alveolar Proteinosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.